Evaluating energy needs in bladder cancer patients
METRICS Study: Metabolic Evaluation Through Resting Indirect Calorimetry in Bladder Cancer
This study is testing how much energy bladder cancer patients need and how their muscles are working during treatment to see if it can help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Kansas Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Kansas City, Kansas and 1 other locations) |
| Trial ID | NCT06721260 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the energy requirements and muscle function of patients undergoing treatment for bladder cancer. By monitoring resting energy expenditure (REE) and levels of growth differentiation factor 15 (GDF-15), the study seeks to identify early signs of cachexia, a condition that can significantly impact treatment outcomes. The findings could lead to improved strategies for managing cachexia and enhancing patient care during and after treatment. The study focuses on patients receiving platinum-based chemotherapy followed by radical cystectomy, aiming to gather data that could inform future therapeutic approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with confirmed bladder cancer who are scheduled to receive platinum-based chemotherapy followed by radical cystectomy.
Not a fit: Patients who have previously undergone chemotherapy or radiotherapy for bladder cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and more effective treatment of cachexia in bladder cancer patients.
How similar studies have performed: While the approach of evaluating energy needs in cancer patients is not entirely novel, the specific focus on bladder cancer and the integration of GDF-15 monitoring represents a potentially untested area that could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed cancer diagnosis * Scheduled for platinum-based chemotherapy followed by radical cystectomy * Adequate renal and cardiac function for platinum-based chemotherapy Exclusion Criteria: * Prior chemotherapy or radiotherapy for bladder cancer * Severe cardiac, renal, hepatic, respiratory or metabolic diseases * Pregnant or breastfeeding * Uncontrolled conditions that could affect study outcomes
Where this trial is running
Kansas City, Kansas and 1 other locations
- University of Kansas Medical Center — Kansas City, Kansas, United States (Recruiting)
- University of Kansas Medical Center — Kansas City, Kansas, United States (Recruiting)
Study contacts
- Principal investigator: Jill M Hamilton-Reeves, PhD, RD, CSO — University of Kansas Medical Center
- Study coordinator: Jill M. Hamilton-Reeves, PhD, RD, CSO
- Email: jhamilton-reeves@kumc.edu
- Phone: 913-588-7650
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.